Category: Technology Licenses
Created On: 2022-04-28
Record Count: 7
- Wound Care
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 3465
Microcyn Technology is a unique shelf-stable pH-neutral oxychlorine compound. Microcyn has been studied for its clinical benefits and safety, a number of these findings peer-reviewed and published. These studies demonstrate that the Microcyn Technology delivers wound healing benefits, reduction of inflammation, cure or improvement of infection and antimicrobial activity; all while remaining safe and biocompatible as evidenced in a 2007 study published in the International Wound Journal. The reason for this safety is that mammalian cells have evolved with special pumps to regulate the active ingredients in Microcyn Technology while viruses, spores and bacteria, including drug-resistant bacteria, lack this ability. The technology behind the MicrocynÂ® Technology-based family of products involves a unique, patented electrochemical treatment of dilute saltwater. A pH neutral solution of hypochlorous acid, and its sodium salt, hypochlorite, is generated. Hypochlorous acid is a natural product the human body produces in response to injury.
Several solutions derived from this platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores; increase blood flow to the wound site; and reduce both inflammation and pain while assisting in faster wound closure.
IPSCIO Record ID: 299291
Licensor grants a non-exclusive license to use the Licensor Marks solely in connection with the marketing, promotion and sale of the Product(s) in the Field.
Product shall mean any product comprising any formulation containing hypochlorous acid as its principal active ingredient including that product known as NVC-101.
NVC-101 is a topical antimicrobial that can decrease the bacterial bioburden of chronic wounds.
IPSCIO Record ID: 26208
Patent applications relate to the new projects treatment of mustard gas, Nimbus treatment of lumber, and antimicrobial and antiproteolytic wound dressing and method. Nimbus (Nimbus or 'Nimbus technology'), a family of polymers that are bio-engineered to have antimicrobial, super-absorbent, and other properties that can be used in a wide range of applications, such as wound dressings and apparel.
MultiStat (MutltiStat),is a family of patented matrix metalloproteinase inhibitors (MMPIs) that are believe to have significant benefit in the maintenance, healing and repair of skin and eyes. Independent laboratories as well as in-house research show that MultiStat is effective in medical (wound care) and consumer (cosmetic) applications. MultiStat is currently being sold as a performance ingredient to several cosmetics companies.
The Licensee's four core technologies are Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUSÂ®), a family of advanced polymers bio-engineered to have antimicrobial, hemostatic, and other properties that can be used in a wide range of applications; Stay FreshÂ® is a unique chemical formulation for textiles with a durable antimicrobial agent effective against an array of bacteria even after numerous laundering cycles; NimbuDermÂ® is a novel copolymer for application as a persistent hand sanitizer with long lasting protection against germs; and MultiStat, a family of advanced patented methods and compounds shown to be effective in skin therapy applications.
IPSCIO Record ID: 203522
– to use Bulk Active Material to produce or have produced Finished Products only for making Sales in the Field of Use, either directly, through its Affiliates or through Distributors or Sub-Licensees, in the Territory; – and, to use Bulk Active Material to conduct internal research and development activities relative to and for the benefit of making Joint Improvements or Licensee Improvements to Finished Products.
For the License to Trademark for the Bulk Active Material, Licensor grants, only in the Territory, to Licensee a non-exclusive, transferable, sub-licensable right in the Field of Use to use, copy, publish, display, distribute and disseminate, on or in any tangible form or electronic media, the Trademark for the Bulk Active Material only in connection with the Sale of Finished Products in the Field of Use and associated marketing collaterals and packaging in accordance with the Trademark Style Guide and Requirements.
TB4 is a naturally occurring 43-amino acid peptide present in virtually all human cells. TB4 represents a new class of wound healing drug and is different from other wound repair factors, such as growth factors, in that it promotes endothelial cell differentiation and keratinocyte cell migration, down-regulates a number of inflammatory cytokines and chemokines, and has a very low molecular weight, allowing it to diffuse relatively long distances through tissues. A key mechanism of action is TB4's ability to regulate the cell-building protein, actin, a vital component of the cytoskeleton. It has been the subject of a significant amount of research at the NIH and a number of other academic institutions, and has been reported to be effective in the repair of dermal and corneal wounds in numerous animal models under a variety of conditions.
Patents are for Methods of treating Epidennolysis Bullosa and Other similar Dermatological Indications with Thymosin Beta 4, Analogues, isoforms and Other Derivatives, Treatment of Infections and Other Disorders, Thymosin B4 Promotes Wound Repair, Methods of Treating and Preventing Anthrax Induced Pathologies with Thymosin Beta 4 Analogs, isoforms and Other Derivatives incorporated into 2600-108, Methods of Healing or Preventing Inflammation, Damage and Other Changes that Occur prior to, During or Immediately after a Myocardial Event with Thymosin Beta 4, Analogues, isoforms, and other Derivatives, Methods of Healing, Treating and/ or Reversal of Stenosis or Â·Restenosis of the Myocardium and Coronary Vessels, Heart Valves and Septa Injuries or Defects Using Thymosin Beta 4, or TB4 Analogues, isoforms, Antibodies or anti-sense Peptides, and, Methods of Treating and Preventing Physical, Cognitive and Biological Damage Due to Ionizing Radiation Exposure by Administering LKKTET Peptides, TB4, analogues, isoforms and Other Derivatives.
Finished Product means any prescription or over-the-counter pharmaceutical product, or a medical device, in the Field of Use containing the Bulk Active Material.
The trademark will be determined by Licensee and approved by Licensor.
IPSCIO Record ID: 26365
IPSCIO Record ID: 614
Patent means – United States Patent No. 6,136,341.
The patented technologies and processes related to CellerateRxTM, an advanced collagen based wound care product formulation. These new licenses are limited to the human health care market for external wound care, and include any new product developments based on the licensed patent and processes.
IPSCIO Record ID: 7364
Under the Agreement, the Licensor grants the Licensee exclusive rights to use the Nimbus intellectual property in hydrophilic polyurethane foam for wound care applications and for securing intravenous tubings and catheters on products sold in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine, Uzbekistan, Russia and their territories and possessions.
NIMBUSÂ® is based on non-toxic, long chain polymers with high charge density that provide superior efficacy via a physical action on microbes. By destroying bacteria at the cellular level, NIMBUSÂ® eliminates the risk of developing drug resistance. The technology is highly effective against a multitude of bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococcus (VRE), two of the most significant antibiotic-resistant organisms responsible for hospital infections.
The Marks and Trademarks of Licensor include without limitation Quick-Med Technologies, QMT, Quick-Med, NIMBUS, and accompanying logos and trade dress, including the QMT Cross Official Logo
Intrinsically Bactericidal Absorbent Dressing and Method of Fabrication – IN/PCT/2001/00776/MUM
Method of Attaching An Antimicrobial Cationic Electrolyte To The Surface of A Substrate – PCT/US2006/32955
Polyelectrolyte Complex for Imparting Antimicrobial Properties to a Substrate – PCT/US2009/051163